Recent Investment Analysts’ Ratings Updates for Jade Biosciences (JBIO)

A number of research firms have changed their ratings and price targets for Jade Biosciences (NASDAQ: JBIO):

  • 11/16/2026 – Jade Biosciences had its “buy” rating reaffirmed by BTIG Research.
  • 11/16/2026 – Jade Biosciences had its price target lowered by Guggenheim from $47.00 to $41.00. They now have a “buy” rating on the stock.
  • 11/14/2026 – Jade Biosciences was upgraded by Wall Street Zen from “strong sell” to “sell”.
  • 10/27/2026 – Jade Biosciences had its “buy” rating reaffirmed by BTIG Research. They now have a $77.00 price target on the stock.
  • 10/1/2026 – Jade Biosciences had its “outperform” rating reaffirmed by Wedbush. They now have a $47.00 price target on the stock.
  • 10/1/2026 – Jade Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $55.00 price target on the stock.

Jade Biosciences Trading Down 2.8%

NASDAQ:JBIO traded down $0.43 during trading hours on Tuesday, hitting $14.91. The company’s stock had a trading volume of 634,486 shares, compared to its average volume of 772,657. Jade Biosciences, Inc. has a 52-week low of $11.02 and a 52-week high of $28.00. The stock has a market capitalization of $948.53 million, a P/E ratio of -8.02 and a beta of 1.81. The stock has a fifty day moving average of $15.23 and a 200-day moving average of $18.14.

Jade Biosciences (NASDAQ:JBIO – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.31. On average, sell-side analysts forecast that Jade Biosciences, Inc. will post -2.89 earnings per share for the current year.

Jade Biosciences is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease. The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys. Jade’s pipeline is focused on potential therapies for autoimmune conditions.

Read More

Receive News & Ratings for Jade Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.